Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SHC1
REST API REST API
Homo sapiens
SHC1 is differentially expressed in 299 experiments: 172 organism parts: lung, liver, ... (170 more);, 245 disease states: normal, control, ... (243 more);, 93 cell types 516 cell lines 42 compound treatments and 80 other conditions.
Synonyms p66, SHC
Orthologs SHC1_BOVIN (Bos taurus)   SHC1 (Gallus gallus)   SHC1 (Danio rerio)   Shc1 (Rattus norvegicus)   ENSCING00000006400 (Ciona intestinalis)   Shc1 (Mus musculus)   Shc (Drosophila melanogaster)   shc1 (Xenopus laevis)   SHC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, neuron differentiation, cytosol, response to hydrogen peroxide, insulin-like growth factor receptor binding, plasma membrane, actin cytoskeleton reorganization, protein binding, cytoplasm, cell-cell adhesion, epidermal growth factor receptor signaling pathway, response to toxin, positive regulation of cell proliferation, MAPKKK cascade, insulin receptor binding, mitochondrial matrix, insulin receptor signaling pathway, blood coagulation, response to hypoxia, phospholipid binding, ephrin receptor binding, endosome membrane, epidermal growth factor receptor binding, fibroblast growth factor receptor signaling pathway, activation of MAPK activity, actin cytoskeleton organization, Ras protein signal transduction, neuron projection development, nucleus, heart development, aging, positive regulation of DNA replication, phosphoprotein binding, regulation of growth, mitochondrion, leukocyte migration, response to nicotine, organ regeneration, phosphotyrosine binding, response to insulin stimulus, nerve growth factor receptor signaling pathway, Shc-EGFR complex, protein complex binding, positive regulation of smooth muscle cell proliferation, response to glucocorticoid stimulus, positive regulation of vasoconstriction, intracellular signal transduction, transmembrane receptor protein tyrosine kinase adaptor activity, response to organic cyclic compound, regulation of epidermal growth factor-activated receptor activity
InterPro Term SH2, PID_domain, PTyr_interaction_dom
UniProt Accession P29353, Q5T182, Q5T181, Q5T189, Q5T188, Q5T187, Q8NFT1, Q8NFT0, B4DL02, E9PFM5
Search EB-eye ENSG00000160691
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
510 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (46 experiments)

Factor Value U/D Experiments
stromal cell
3
E-GEOD-1460, E-MEXP-1327, E-GEOD-10797
CD4+ T cell
2
E-MTAB-25, E-MTAB-24
adipocyte
2
E-AFMX-5, E-MTAB-25
1
2
E-TABM-145, E-TABM-130
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
testis - germ cell
2
E-AFMX-5, E-TABM-145
87 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (69 experiments)

Factor Value U/D Experiments
control
5
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-3185, E-GEOD-20602 ... (5 experiments)
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-995
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
lung adenocarcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-4412
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-37, E-MTAB-62, E-GEOD-96
239 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
placebo
2
E-MEXP-1335, E-MEXP-1327
none
4
5
E-GEOD-5824, E-GEOD-5741, E-GEOD-412, E-MEXP-1958, E-GEOD-995, ... (9 experiments)
heregulin
1
E-GEOD-6462
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
17-allylamino-geldanamycin
1
1
E-GEOD-5258
36 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21887

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (11 experiments)

Genotype
studied in E-GEOD-22056, E-MEXP-1437, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-22278, E-TABM-263, E-MEXP-1220, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.456 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM